We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Corautus Genetics has announced that the final efficacy results from its GENASIS Phase IIb trial, which evaluated VEGF-2 in Class III or IV angina, did not achieve a statistically significant difference from placebo in any active dose group for the primary efficacy endpoint.
Schwarz Pharma has announced that its rotigotine transdermal patch demonstrated a favorable safety and tolerability profile during both the titration and maintenance phases of three clinical studies, including two Phase III trials.
Discovery Laboratories has announced that additional clinical data from its SELECT and STAR Phase III clinical trials of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants were presented at the European Academy of Paediatrics Congress in Barcelona.
Theravance has announced additional results from its ATLAS 1 and ATLAS 2 studies assessing the safety and efficacy of telavancin, a rapidly bactericidal injectable antibiotic with multiple mechanisms of action, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria.
Pharming announced that it has received a grant from the FDA's Office of Orphan Products Development (OPD) for the clinical development of recombinant human C1 inhibitor (rhC1INH or Rhucin) for treatment of attacks of hereditary angioedema (HAE).
MacroGenics announced that its lead product candidate, MGA031, a humanized, Fc-engineered anti-CD3 monoclonal antibody, has received orphan drug designation from the FDA for treatment of recent-onset Type 1 diabetes mellitus.
The National Eye Institute (NEI) of the NIH will fund a multicenter clinical trial to compare two drugs currently used to treat advanced age-related macular degeneration (AMD).
Protalex has announced data from its Phase I clinical trial of PRTX-100, which is in development for autoimmune disorders including rheumatoid arthritis and idiopathic thrombocytopenic purpura (ITP), a disorder in which the blood does not clot.